Mark Bogart Joins B-Secur as SVP of U.S. Healthcare

B-Secur has appointed Mark Bogart as senior vice president of U.S. Healthcare to help expand the company’s footprint in the U.S. market.
 
Bogart will identify, develop, and build long-term agreements with medical device and digital health companies as well as cultivate and manage customer relationships with existing partners. He will also focus on delivering the company’s medical strategy for its newly launched HeartKey 2.0 technology.
 
Launched in April at Heart Rhythm 2022, HeartKey 2.0 significantly reduces EKG signal noise, elevating EKG interpretation to new heights of efficiency and accuracy for clinicians and facilitating the trend towards greater remote cardiac monitoring. It also offers a range of FDA-cleared health algorithms and actionable wellness insights.
 
“Supported by a best-in-class engineering and product development team, B-Secur is at the forefront of signal conditioning and EKG rhythm analysis,” Bogart said. “The opportunity to engage and bring forward HeartKey 2.0 creates tremendous opportunities across the U.S. medtech space and ultimately improves workflow, patient care and clinical outcomes.”
 
Bogart joins B-Secur from AliveCor, where he worked as SVP of the U.S. Healthcare Division. In his previous role, he helped establish KardiaMobile 6L in the B2B markets, validated a direct reimbursement model, and developed new sales and strategic opportunities with key opinion leaders, directing healthcare systems, and progressive companies in digital health. He joins B-Secur with a track record of working with corporate, small, and scale-up businesses and believes the company’s new technology has the power to evolve the cardiovascular space.
 
“Since the launch of HeartKey 2.0 we have seen a strong growing demand across our key consumer and medical customers,” B-Secur Chief Commercial Officer Ben Carter said. “Mark brings a wealth of leadership and business experience from across the medical industry. He has worked with some of the biggest medical device and platform companies in the world and has deep medical industry knowledge. I’m excited that Mark has agreed to join B-Secur and I look forward to working with him as we continue to grow our business, especially in the U.S.”
 
Founded in Belfast, Northern Ireland, B-Secur employs almost 100 people in the United States, the U.K. and Ireland. The biosensing algorithm company licences its technology to a number of medical and consumer technology customers.